Atea Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AVIR Nasdaq 2834 ateapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atea Pharmaceuticals, Inc.

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround - Feb 3rd, 2026 8:20 am
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - Feb 3rd, 2026 8:06 am
Spotlight On Atea Pharmaceuticals And 2 Other Noteworthy Penny Stocks - Jan 23rd, 2026 11:05 am
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Jan 19th, 2026 9:19 am
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference - Jan 15th, 2026 12:32 pm
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock - Jan 13th, 2026 11:30 am
Atea Pharmaceuticals to highlight strategic priorities for FY26 - Jan 9th, 2026 5:17 am
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference - Jan 8th, 2026 5:00 am
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 5:00 am
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Dec 22nd, 2025 5:00 am
Nano Dimension And 2 Other Penny Stocks With Promising Potential - Dec 17th, 2025 11:05 am
We're Keeping An Eye On Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Rate - Dec 10th, 2025 5:29 am
ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman - Dec 2nd, 2025 2:46 pm
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... - Nov 19th, 2025 6:02 pm
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference - Nov 19th, 2025 5:00 am
3 Promising Penny Stocks With Market Caps As Low As $200M - Nov 13th, 2025 5:05 am
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 12th, 2025 2:05 pm
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025 - Nov 7th, 2025 6:00 am
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 - Nov 5th, 2025 5:00 am
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 - Oct 22nd, 2025 5:00 am